| Primary |
| Drug Use For Unknown Indication |
28.3% |
| Diffuse Large B-cell Lymphoma |
16.8% |
| Non-hodgkin's Lymphoma |
10.0% |
| Product Used For Unknown Indication |
9.9% |
| Rheumatoid Arthritis |
7.2% |
| B-cell Lymphoma |
5.4% |
| Premedication |
4.6% |
| Lymphoma |
3.9% |
| Chronic Lymphocytic Leukaemia |
3.7% |
| Mantle Cell Lymphoma |
2.3% |
| Off Label Use |
1.9% |
| Systemic Lupus Erythematosus |
1.0% |
| Idiopathic Thrombocytopenic Purpura |
0.9% |
| Prophylaxis |
0.9% |
| Waldenstrom's Macroglobulinaemia |
0.8% |
| Hypertension |
0.6% |
| Prophylaxis Against Transplant Rejection |
0.5% |
| Anaemia Haemolytic Autoimmune |
0.4% |
| Hodgkin's Disease |
0.4% |
| Wegener's Granulomatosis |
0.4% |
|
| Death |
38.9% |
| Progressive Multifocal Leukoencephalopathy |
10.3% |
| Febrile Neutropenia |
6.1% |
| White Blood Cell Count Decreased |
4.1% |
| Pneumonia |
3.7% |
| Vomiting |
3.7% |
| Thrombocytopenia |
3.4% |
| Pyrexia |
3.4% |
| Sepsis |
2.7% |
| Infusion Related Reaction |
2.7% |
| Pneumocystis Jiroveci Pneumonia |
2.6% |
| Neutropenia |
2.5% |
| Respiratory Failure |
2.5% |
| Weight Decreased |
2.5% |
| Hepatitis B |
2.2% |
| Renal Failure |
1.9% |
| Rheumatoid Arthritis |
1.8% |
| Weight Increased |
1.7% |
| Urticaria |
1.7% |
| Myocardial Infarction |
1.6% |
|
| Secondary |
| Product Used For Unknown Indication |
15.4% |
| Drug Use For Unknown Indication |
12.5% |
| Diffuse Large B-cell Lymphoma |
10.6% |
| Chronic Lymphocytic Leukaemia |
9.9% |
| Non-hodgkin's Lymphoma |
8.2% |
| Off Label Use |
5.8% |
| Rheumatoid Arthritis |
5.3% |
| B-cell Lymphoma |
5.3% |
| Lymphoma |
5.1% |
| Premedication |
5.0% |
| Mantle Cell Lymphoma |
4.2% |
| Burkitt's Lymphoma |
2.1% |
| Prophylaxis |
2.0% |
| Idiopathic Thrombocytopenic Purpura |
1.5% |
| Hypertension |
1.5% |
| Nausea |
1.2% |
| Renal Transplant |
1.2% |
| Systemic Lupus Erythematosus |
1.1% |
| Dermatomyositis |
1.1% |
| Behcet's Syndrome |
1.0% |
|
| Death |
36.8% |
| Progressive Multifocal Leukoencephalopathy |
10.6% |
| Vomiting |
5.9% |
| White Blood Cell Count Decreased |
5.5% |
| Pyrexia |
4.7% |
| Febrile Neutropenia |
4.5% |
| Sepsis |
3.7% |
| Weight Decreased |
3.7% |
| Thrombocytopenia |
3.2% |
| Urinary Tract Infection |
2.5% |
| Pneumonia |
2.4% |
| Pancytopenia |
2.3% |
| Respiratory Failure |
1.9% |
| Neutropenia |
1.9% |
| Renal Failure |
1.9% |
| Tumour Lysis Syndrome |
1.8% |
| Malaise |
1.7% |
| Rash |
1.7% |
| Myelodysplastic Syndrome |
1.6% |
| Pulmonary Embolism |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
16.0% |
| Non-hodgkin's Lymphoma |
10.0% |
| Chronic Lymphocytic Leukaemia |
9.4% |
| Idiopathic Thrombocytopenic Purpura |
8.7% |
| Lymphoma |
7.2% |
| Rheumatoid Arthritis |
7.0% |
| Drug Use For Unknown Indication |
5.9% |
| Prophylaxis |
4.9% |
| Mantle Cell Lymphoma |
4.4% |
| Renal Transplant |
4.4% |
| B-cell Lymphoma |
3.2% |
| Hypertension |
2.8% |
| Premedication |
2.4% |
| Chemotherapy |
2.2% |
| Pain |
2.2% |
| Diffuse Large B-cell Lymphoma |
2.1% |
| Prophylaxis Against Transplant Rejection |
2.0% |
| Stem Cell Transplant |
1.8% |
| Constipation |
1.8% |
| Pyrexia |
1.6% |
|
| White Blood Cell Count Decreased |
14.6% |
| Thrombocytopenia |
9.6% |
| Drug Ineffective |
6.9% |
| Rash |
6.7% |
| Therapeutic Response Decreased |
6.3% |
| Pyrexia |
6.1% |
| Sepsis |
4.9% |
| Weight Decreased |
4.7% |
| Platelet Count Decreased |
4.5% |
| Vomiting |
4.3% |
| Neutropenia |
4.2% |
| Pneumonia |
4.0% |
| Non-hodgkin's Lymphoma |
3.6% |
| Death |
3.3% |
| Pancytopenia |
3.3% |
| Urinary Tract Infection |
3.1% |
| Lymphoma |
2.5% |
| Sarcoidosis |
2.5% |
| White Blood Cell Count Increased |
2.5% |
| Rheumatoid Arthritis |
2.4% |
|
